Jeffrey S Hoch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4732068/publications.pdf

Version: 2024-02-01

66336 98792 6,078 211 42 67 citations h-index g-index papers 220 220 220 9522 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Economics (United Kingdom), 2002, 11, 415-430.	1.7	435
2	Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics (United Kingdom), 2004, 13, 461-475.	1.7	285
3	Cost implications of testing strategy in patients with syncope. Journal of the American College of Cardiology, 2003, 42, 495-501.	2.8	150
4	Hospital Costs and Length of Stay Among Homeless Patients Admitted to Medical, Surgical, and Psychiatric Services. Medical Care, 2011, 49, 350-354.	2.4	141
5	Comparative Operative Outcomes of Early and Delayed Cholecystectomy for Acute Cholecystitis. Annals of Surgery, 2014, 259, 10-15.	4.2	140
6	Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMC Health Services Research, 2006, 6, 68.	2.2	131
7	Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness. British Journal of Psychiatry, 1999, 174, 346-352.	2.8	114
8	Health Status, Quality of Life, Residential Stability, Substance Use, and Health Care Utilization among Adults Applying to a Supportive Housing Program. Journal of Urban Health, 2011, 88, 1076-1090.	3.6	105
9	Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children. JAMA - Journal of the American Medical Association, 2017, 318, 245.	7.4	105
10	Pathogen inactivation: making decisions about new technologies. Transfusion, 2007, 47, 2338-2347.	1.6	98
11	End-of-Life Care for Lung Cancer Patients in the United States and Ontario. Journal of the National Cancer Institute, 2011, 103, 853-862.	6.3	86
12	Cost Effectiveness of <i>EML4-ALK</i> Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced <i>ALK</i> -Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2014, 32, 1012-1019.	1.6	85
13	Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ, The, 2014, 349, g5459-g5459.	6.0	84
14	A population-based analysis of the clinical course of 10,304 patients with acute cholecystitis, discharged without cholecystectomy. Journal of Trauma and Acute Care Surgery, 2013, 74, 26-31.	2.1	82
15	The economic burden of cancer care in Canada: a population-based cost study. CMAJ Open, 2018, 6, E1-E10.	2.4	79
16	Cost-effectiveness of screening for anal precancers in HIV-positive men. Aids, 2011, 25, 635-642.	2.2	77
17	Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. Cmaj, 2015, 187, E190-E197.	2.0	76
18	Comparison of five measures of motivation to quit smoking among a sample of hospitalized smokers. Journal of General Internal Medicine, 2000, 15, 16-23.	2.6	75

#	Article	lF	Citations
19	The assessment for living with aphasia: Reliability and construct validity. International Journal of Speech-Language Pathology, 2014, 16, 82-94.	1.2	7 3
20	Phase-specific and lifetime costs of cancer care in Ontario, Canada. BMC Cancer, 2016, 16, 809.	2.6	71
21	Improving chronic disease prevention and screening in primary care: results of the BETTER pragmatic cluster randomized controlled trial. BMC Family Practice, 2013, 14, 175.	2.9	70
22	Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet Journal of Rare Diseases, 2019, 14, 12.	2.7	68
23	Cost-Effectiveness Analysis: What It Really Means for Transfusion Medicine Decision Making. Transfusion Medicine Reviews, 2009, 23, 1-12.	2.0	64
24	Health care costs associated with hepatocellular carcinoma: A population-based study. Hepatology, 2013, 58, 1375-1384.	7.3	64
25	Advocacy for outpatient cardiac rehabilitation globally. BMC Health Services Research, 2016, 16, 471.	2.2	63
26	Change of Outcomes in Pediatric Intestinal Failure: Use of Time-Series Analysis to Assess the Evolution of an Intestinal Rehabilitation Program. Journal of the American College of Surgeons, 2016, 222, 1180-1188.e3.	0.5	62
27	Health System Costs for Stage-Specific Breast Cancer: A Population-Based Approach. Current Oncology, 2014, 21, 281-293.	2.2	57
28	Economic Evaluation of Web-Based Compared with In-Person Follow-up After Total Joint Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2014, 96, 1910-1916.	3.0	56
29	Pattern of antidepressant use and duration of depression-related absence from work. British Journal of Psychiatry, 2003, 183, 507-513.	2.8	56
30	Cost-effectiveness analysis of arthroscopic surgery compared with non-operative management for osteoarthritis of the knee. BMJ Open, 2016, 6, e009949.	1.9	54
31	Increased risk of miscarriage among women experiencing physical or sexual intimate partner violence during pregnancy in Guatemala City, Guatemala: cross-sectional study. BMC Pregnancy and Childbirth, 2011, 11, 49.	2.4	53
32	Cost and Cost-effectiveness of Hospital vs Residential Crisis Care for Patients Who Have Serious Mental Illness. Archives of General Psychiatry, 2002, 59, 357.	12.3	52
33	A costâ€effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. Cancer, 2015, 121, 1785-1792.	4.1	51
34	Is ambulatory monitoring for "community-acquired―syncope economically attractive? A cost-effectiveness analysis of a randomized trial of external loop recorders versus Holter monitoring. American Heart Journal, 2005, 150, 1065.e1-1065.e5.	2.7	50
35	A Clinician's Guide to Correct Cost-Effectiveness Analysis: Think Incremental Not Average. Canadian Journal of Psychiatry, 2008, 53, 267-274.	1.9	50
36	Cost-effectiveness of a fracture liaison serviceâ€"a real-world evaluation after 6Âyears of service provision. Osteoporosis International, 2016, 27, 231-240.	3.1	50

#	Article	IF	CITATIONS
37	Impact of a Specialized Early Intervention Service for Psychotic Disorders on Patient Characteristics, Service Use, and Hospital Costs in a Defined Catchment Area. Canadian Journal of Psychiatry, 2006, 51, 895-903.	1.9	47
38	Cost-Effectiveness of Two Vocational Rehabilitation Programs for Persons With Severe Mental Illness. Psychiatric Services, 2002, 53, 1118-1124.	2.0	45
39	A Review and Meta-analysis of Colorectal Cancer Utilities. Medical Decision Making, 2014, 34, 809-818.	2.4	45
40	A systematic review of cost-effectiveness analyses of complex wound interventions reveals optimal treatments for specific wound types. BMC Medicine, 2015, 13, 90.	5.5	45
41	The price of performance: a cost and performance analysis of the implementation of cellâ€free fetal DNA testing for Down syndrome in Ontario, Canada. Prenatal Diagnosis, 2014, 34, 350-356.	2.3	44
42	Pattern of antidepressant use and duration of depression-related absence from work. British Journal of Psychiatry, 2003, 183, 507-513.	2.8	43
43	To plug or not to plug: A cost-effectiveness analysis for complex anal fistula. Surgery, 2010, 147, 72-78.	1.9	43
44	Cost-effectiveness of Intensity-modulated Radiotherapy in Prostate Cancer. Clinical Oncology, 2012, 24, 521-531.	1.4	43
45	An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliative Medicine, 2015, 29, 918-928.	3.1	43
46	Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke. Stroke, 2016, 47, 2380-2385.	2.0	43
47	Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer, 2014, 14, 586.	2.6	41
48	Use and Costs of Ambulatory Care Services Among Medicare Enrollees With Schizophrenia. Psychiatric Services, 2001, 52, 786-792.	2.0	40
49	Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. PLoS ONE, 2017, 12, e0172864.	2.5	40
50	Design of an algorithm to identify persons with mental illness in a police administrative database. International Journal of Law and Psychiatry, 2005, 28, 1-11.	0.9	39
51	Developing and testing an intervention to prevent homelessness among individuals discharged from psychiatric wards to shelters and †No Fixed Address'. Journal of Psychiatric and Mental Health Nursing, 2008, 15, 569-575.	2.1	38
52	Impact of rituximab on treatment outcomes of patients with diffuse large bâ€cell lymphoma: a populationâ€based analysis. British Journal of Haematology, 2012, 158, 481-488.	2.5	37
53	Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. CMAJ Open, 2013, 1, E151-E158.	2.4	37
54	An interprofessional nurse-led mental health promotion intervention for older home care clients with depressive symptoms. BMC Geriatrics, 2014, 14, 62.	2.7	37

#	Article	IF	CITATIONS
55	Cost-effectiveness of Intensity-modulated Radiotherapy in Oropharyngeal Cancer. Clinical Oncology, 2012, 24, 532-538.	1.4	36
56	When Could a Stigma Program to Address Mental Illness in the Workplace Break Even?. Canadian Journal of Psychiatry, 2014, 59, 34-39.	1.9	36
57	Effectiveness of Alberta Family Integrated Care on infant length of stay in level II neonatal intensive care units: a cluster randomized controlled trial. BMC Pediatrics, 2020, 20, 535.	1.7	36
58	Advantages of the Net Benefit Regression Framework for Economic Evaluations of Interventions in the Workplace. Journal of Occupational and Environmental Medicine, 2014, 56, 441-445.	1.7	35
59	A Time-Trend Economic Analysis of Cancer Drug Trials. Oncologist, 2015, 20, 729-736.	3.7	35
60	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 93-107.	1.2	35
61	Estimating linear regression models in the presence of a censored independent variable. Statistics in Medicine, 2004, 23, 411-429.	1.6	34
62	Informing Canada's Cancer Drug Funding Decisions with Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review. Current Oncology, 2013, 20, 121-124.	2.2	33
63	Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open, 2020, 10, e032884.	1.9	32
64	Work-related experiences of head and neck cancer survivors: an exploratory and descriptive qualitative study. Disability and Rehabilitation, 2018, 40, 1252-1258.	1.8	31
65	Enhancing Self-Efficacy for Help-Seeking Among Transition-Aged Youth in Postsecondary Settings With Mental Health and/or Substance Use Concerns, Using Crowd-Sourced Online and Mobile Technologies: The Thought Spot Protocol. JMIR Research Protocols, 2016, 5, e201.	1.0	31
66	HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?. International Journal of Technology Assessment in Health Care, 2014, 30, 179-187.	0.5	30
67	Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients. Journal of the National Cancer Institute, 2013, 105, 1078-1085.	6.3	29
68	CANADIAN CANCER RISK MANAGEMENT MODEL: EVALUATION OF CANCER CONTROL. International Journal of Technology Assessment in Health Care, 2013, 29, 131-139.	0.5	29
69	The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder: the feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol. BMC Psychiatry, 2018, 18, 230.	2.6	29
70	Hospital Utilization Among Rural Children Served by Pediatric Neurology Telemedicine Clinics. JAMA Network Open, 2019, 2, e199364.	5.9	29
71	Developing clinical decision tools to implement chronic disease prevention and screening in primary care: the BETTER 2 program (building on existing tools to improve chronic disease prevention and) Tj ETQq1 1 C).78 4.3 14 rg	gBT2\$Overloc
72	Prescription drug benefits and Canada's uninsured. International Journal of Law and Psychiatry, 2005, 28, 496-513.	0.9	27

#	Article	IF	CITATIONS
73	A guide to economic evaluation: Methods for cost-effectiveness analysis of person-level data. Journal of Traumatic Stress, 2006, 19, 787-797.	1.8	27
74	Barriers to Mental Health Service Use Among Workers With Depression and Work Productivity. Journal of Occupational and Environmental Medicine, 2015, 57, 726-731.	1.7	27
75	Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions. Pharmacoeconomics, 2007, 25, 807-816.	3.3	26
76	Selected Use of Telemedicine in Intensive Care Units Based on Severity of Illness Improves Cost-Effectiveness. Telemedicine Journal and E-Health, 2018, 24, 21-36.	2.8	26
77	A review of economic evaluations of genetic testing services and interventions (2004–2009). Genetics in Medicine, 2011, 13, 89-94.	2.4	25
78	The Evaluation and Use of Economic Evidence to Inform Cancer Drug Reimbursement Decisions in Canada. Pharmacoeconomics, 2013, 31, 229-236.	3.3	24
79	Early cholecystectomy for acute cholecystitis: a population-based retrospective cohort study of variation in practice. CMAJ Open, 2013, 1, E62-E67.	2.4	24
80	Early Cholecystectomy for Acute Cholecystitis Offers the Best Outcomes at the Least Cost: A Model-Based Cost-Utility Analysis. Journal of the American College of Surgeons, 2016, 222, 185-194.	0.5	24
81	Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference. Vox Sanguinis, 2007, 93, 179-182.	1.5	22
82	Mental Illness and Police Interactions in a Mid-Sized Canadian City: What the Data Do and Do Not Say. Canadian Journal of Community Mental Health, 2009, 28, 49-66.	0.4	22
83	A Population-Based Study of the Epidemiology of Pancreatic Cancer: A Brief Report. Current Oncology, 2015, 22, 478-484.	2.2	22
84	Estimating the Costs of Intensity-Modulated and 3-Dimensional Conformal Radiotherapy in Ontario. Current Oncology, 2016, 23, 228-238.	2.2	22
85	Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. JAMA Surgery, 2019, 154, e193019.	4.3	22
86	An Introduction to Economic Evaluation: What's in a Name?. Canadian Journal of Psychiatry, 2005, 50, 159-166.	1.9	21
87	Improving Efficiency and Value in Palliative Care with Net Benefit Regression: An Introduction to a Simple Method for Cost-Effectiveness Analysis with Person-Level Data. Journal of Pain and Symptom Management, 2009, 38, 54-61.	1.2	21
88	Cost, Effectiveness, and Cost-Effectiveness of a Collaborative Mental Health Care Program for People Receiving Short-Term Disability Benefits for Psychiatric Disorders. Canadian Journal of Psychiatry, 2009, 54, 379-388.	1.9	21
89	Changing costs of type 1 diabetes care among US children and adolescents. Pediatric Diabetes, 2020, 21 , $644-648$.	2.9	21
90	Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions. Healthcare Policy, 2011, 6, 27-35.	0.6	20

#	Article	IF	Citations
91	Genetic Testing in Combination with Preventive Donepezil Treatment for Patients with Amnestic Mild Cognitive Impairment. Molecular Diagnosis and Therapy, 2012, 16, 389-399.	3.8	20
92	Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control. Social Science and Medicine, 2014, 122, 130-139.	3.8	20
93	Appointment completion in pediatric neurology telemedicine clinics serving underserved patients. Neurology: Clinical Practice, 2019, 9, 314-321.	1.6	20
94	Association of Adherence to Weight Telemonitoring With Health Care Use and Death. JAMA Network Open, 2020, 3, e2010174.	5.9	20
95	A cost-effectiveness analysis of self-debriefing versus instructor debriefing for simulated crises in perioperative medicine in Canada. Journal of Educational Evaluation for Health Professions, 2017, 13, 44.	12.6	20
96	Using Financial Incentives to Promote Shared Mental Health Care. Canadian Journal of Psychiatry, 2001, 46, 488-495.	1.9	19
97	Population-Based Trends in Systemic Therapy Use and Cost for Cancer Patients in the Last Year of Life. Current Oncology, 2016, 23, 32-41.	2.2	19
98	A cluster-randomized trial to reduce caesarean delivery rates in Quebec: cost-effectiveness analysis. BMC Medicine, 2017, 15, 96.	5. 5	19
99	Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors. PLoS ONE, 2016, 11, e0152944.	2.5	19
100	Technology-Enabled Remote Monitoring and Self-Management — Vision for Patient Empowerment Following Cardiac and Vascular Surgery: User Testing and Randomized Controlled Trial Protocol. JMIR Research Protocols, 2016, 5, e149.	1.0	19
101	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. Healthcare Policy, 2017, 12, 95-108.	0.6	19
102	Opportunities for Improving Inpatient Smoking Cessation Programs: A Community Hospital Experience. Preventive Medicine, 2000, 30, 496-503.	3.4	18
103	Population-Based Home Care Services in Breast Cancer: Utilization and Costs. Current Oncology, 2012, 19, 383-391.	2.2	18
104	Drivers of Cost for Pancreatic Surgery: It's Not About Hospital Volume. Annals of Surgical Oncology, 2018, 25, 3804-3811.	1.5	18
105	How Much Are We Willing to Pay to Prevent A Fall? Cost-Effectiveness of a Multifactorial Falls Prevention Program for Community-Dwelling Older Adults. Canadian Journal on Aging, 2012, 31, 121-137.	1.1	17
106	The effectiveness of an integrated collaborative care model vs. a shifted outpatient collaborative care model on community functioning, residential stability, and health service use among homeless adults with mental illness: a quasi-experimental study. BMC Health Services Research, 2015, 15, 348.	2.2	17
107	Cost-effectiveness analysis of a multifactorial fall prevention intervention in older home care clients at risk for falling. BMC Geriatrics, 2017, 17, 199.	2.7	17
108	Best Practices: Relationship Management Therapy for Patients With Borderline Personality Disorder. Psychiatric Services, 2006, 57, 179-181.	2.0	16

#	Article	IF	Citations
109	Four decades of mental health policy in Ontario, Canada. Administration and Policy in Mental Health and Mental Health Services Research, 2003, 31, 65-73.	2.1	15
110	DO IT Trial: vitamin D Outcomes and Interventions in Toddlers –a TARGet Kids! randomized controlled trial. BMC Pediatrics, 2014, 14, 37.	1.7	15
111	Measuring and illustrating statistical evidence in a cost-effectiveness analysis. Journal of Health Economics, 2008, 27, 476-495.	2.7	14
112	Expanding Paramedicine in the Community (EPIC): study protocol for a randomized controlled trial. Trials, 2014, 15, 473.	1.6	14
113	Economic Evaluation of Hormonal Therapies for Postmenopausal Women with Estrogen Receptor–Positive Early Breast Cancer in Canada. Current Oncology, 2015, 22, 84-96.	2.2	14
114	Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR). PharmacoEconomics - Open, 2017, 1, 255-263.	1.8	14
115	Is knowledge translation adequate? A quality assurance study of staging investigations in early stage breast cancer patients. Breast Cancer Research and Treatment, 2012, 132, 1-7.	2.5	13
116	Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment. Supportive Care in Cancer, 2013, 21, 245-251.	2.2	13
117	Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom. PharmacoEconomics - Open, 2018, 2, 225-231.	1.8	13
118	Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. BMC Cancer, 2019, 19, 552.	2.6	13
119	Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia. JCO Oncology Practice, 2020, 16, e1120-e1133.	2.9	13
120	Use of Antidepressants Among Canadian Workers Receiving Depression-Related Short-Term Disability Benefits. Psychiatric Services, 2003, 54, 724-729.	2.0	12
121	Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 537-547.	1.4	12
122	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. Healthcare Policy, 2017, 12, 95-108.	0.6	12
123	Evidence for the Cost-Effectiveness of Return-to-Work Interventions for Mental Illness Related Sickness Absences: A Systematic Literature Review. Journal of Occupational Rehabilitation, 2021, 31, 26-40.	2.2	12
124	Examining the Family-Level and Economic Impact of Complex Child Disabilities as a Function of Child Hyperactivity and Service Integration. Journal of Developmental and Physical Disabilities, 2013, 25, 181-201.	1.6	11
125	Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 763-765.	1.4	11
126	Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs. Clinical Oncology, 2016, 28, 587-593.	1.4	11

#	Article	IF	CITATIONS
127	Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. Pharmacoeconomics, 2018, 36, 7-15.	3.3	11
128	A cross-sectional study of risk factors for HIV among pregnant women in Guatemala City, Guatemala: lessons for prevention. International Journal of STD and AIDS, 2010, 21, 789-796.	1.1	10
129	Reducing depression in older home care clients: design of a prospective study of a nurse-led interprofessional mental health promotion intervention. BMC Geriatrics, 2011, 11, 50.	2.7	10
130	Preference-based health-related quality of life in the context of aphasia: a research synthesis. Aphasiology, 2015, 29, 763-780.	2.2	10
131	The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study. PharmacoEconomics - Open, 2018, 2, 255-270.	1.8	10
132	How Are Incremental Cost-Effectiveness, Contextual Considerations, and Other Benefits Viewed in Health Technology Assessment Recommendations in the United States?. Value in Health, 2020, 23, 576-584.	0.3	10
133	Role of Comparative Effectiveness Research in Cancer Funding Decisions in Ontario, Canada. Journal of Clinical Oncology, 2012, 30, 4262-4266.	1.6	9
134	Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?. Pharmacoeconomics, 2015, 33, 879-882.	3.3	9
135	Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters. Pharmacoeconomics, 2015, 33, 1083-1090.	3.3	9
136	Economic evaluation of smoking cessation in Ontario's regional cancer programs. Cancer Medicine, 2018, 7, 4765-4772.	2.8	9
137	A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis. Pharmacoeconomics, 2019, 37, 1525-1536.	3.3	9
138	Patient-level resource use for injury admissions in Canada: A multicentre retrospective cohort study. Injury, 2019, 50, 1192-1201.	1.7	9
139	Clinical Outcomes and Costs Following Unplanned Excisions of Soft Tissue Sarcomas in the Elderly. Journal of Surgical Research, 2019, 239, 125-135.	1.6	9
140	The Effect of Patient Observation on Cranial Computed Tomography Rates in Children With Minor Head Trauma. Academic Emergency Medicine, 2020, 27, 832-843.	1.8	9
141	Preventing Psychiatric Discharge to Homelessness. Canadian Journal of Community Mental Health, 2013, 32, 17-28.	0.4	9
142	Flexible Client-Driven In-Home Case Management: An Option to Consider. Care Management Journals: Journal of Case Management; the Journal of Long Term Home Health Care, 2004, 5, 73-86.	0.5	8
143	Can We Afford Consumers Choice in Home Care?. Care Management Journals: Journal of Case Management ; the Journal of Long Term Home Health Care, 2007, 8, 171-178.	0.5	8
144	Cost of Preimplantation Cardiac Imaging in Patients Referred for a Primary-Prevention Implantable Cardioverter-Defibrillator. American Journal of Cardiology, 2008, 102, 588-592.	1.6	8

#	Article	IF	Citations
145	Meaningful Patient Representation Informing Canada's Cancer Drug Funding Decisions: Views of Patient Representatives on the Pan-Canadian Oncology Drug Review. Current Oncology, 2014, 21, 263-266.	2.2	8
146	The impact of stratifying by family history in colorectal cancer screening programs. International Journal of Cancer, 2015, 137, 1119-1127.	5.1	8
147	A Comparison of Healthcare Use and Costs for Workers with Psychiatric Disabilities Employed in Social Enterprises Versus Those Who Are Not Employed and Seeking Work. Community Mental Health Journal, 2019, 55, 202-210.	2.0	8
148	Toward Effective Work Accommodations for Depression. Journal of Occupational and Environmental Medicine, 2019, 61, 75-80.	1.7	8
149	Preventing Homelessness After Discharge from Psychiatric Wards: Perspectives of Consumers and Staff. Journal of Psychosocial Nursing and Mental Health Services, 2013, 51, 24-31.	0.6	8
150	Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada. JCO Oncology Practice, 2020, 16, e1-e18.	2.9	7
151	Health-related quality of life in neonates and infants: a conceptual framework. Quality of Life Research, 2020, 29, 1159-1168.	3.1	7
152	Fixed and flexible formularies as cost-control mechanisms. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 303-315.	1.4	6
153	The Family Standpoint of Investigation: Examining the Correlates and Costs of Parental Stress in a Sample of Families Involved With Ontario Child Welfare. Canadian Journal of Community Mental Health, 2010, 29, 131-154.	0.4	6
154	Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation. Applied Health Economics and Health Policy, 2016, 14, 313-322.	2.1	6
155	Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers?. Journal of the American College of Surgeons, 2021, 233, 90-98.	0.5	6
156	Deriving a mental health outcome measure using the pooled index: an application to psychiatric consumer–survivors in different housing types. Health Services and Outcomes Research Methodology, 2009, 9, 133-143.	1.8	5
157	Overcoming Obstacles in Accessing Unfunded Oral Chemotherapy: Physician Experience and Challenges. Journal of Oncology Practice, 2013, 9, 188-193.	2.5	5
158	Estimating the Net Benefit of a Specialized Return-to-Work Program for Workers on Short-Term Disability Related to a Mental Disorder. Journal of Occupational and Environmental Medicine, 2014, 56, 628-631.	1.7	5
159	A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach. Supportive Care in Cancer, 2017, 25, 2505-2513.	2.2	5
160	Closing the personalized medicine information gap: HER2 test documentation practice. American Journal of Managed Care, 2013, 19, 838-44.	1.1	5
161	Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures. Clinical Therapeutics, 2001, 23, 292-306.	2.5	4
162	Group a Streptococcal Carriage among Residents of an Urban Homeless Shelter. Canadian Journal of Infectious Diseases and Medical Microbiology, 2007, 18, 316-317.	1.9	4

#	Article	IF	Citations
163	Population-Based Utilization of Radiation Therapy by a Canadian Breast Cancer Cohort. Current Oncology, 2014, 21, 715-717.	2.2	4
164	COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008. International Journal of Technology Assessment in Health Care, 2017, 33, 481-486.	0.5	4
165	Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology. PharmacoEconomics - Open, 2017, 1, 167-173.	1.8	4
166	Econometric Considerations When Using the Net Benefit Regression Framework to Conduct Cost-effectiveness Analysis. Contributions To Economic Analysis, 2018, , 119-143.	0.1	4
167	Review article: A primer for clinical researchers in the emergency department: Part X. Understanding economic evaluation alongside emergency medicine research. EMA - Emergency Medicine Australasia, 2019, 31, 710-714.	1.1	4
168	Parent Experience and Cost Savings Associated With a Novel Tele-physiatry Program for Children Living in Rural and Underserved Communities. Archives of Physical Medicine and Rehabilitation, 2022, 103, 8-13.	0.9	4
169	Medical savings accounts: opportunities for cost savings?. International Transactions in Operational Research, 2006, 13, 493-513.	2.7	3
170	The Iscore Predicts Total Healthcare Costs Early after Hospitalization for an Acute Ischemic Stroke. International Journal of Stroke, 2015, 10, 1179-1186.	5.9	3
171	Hospitalization cost of conventional psychiatric care compared to broad-spectrum micronutrient treatment: literature review and case study of adult psychosis. International Journal of Mental Health Systems, 2017, 11, 14.	2.7	3
172	Xylitol for the prevention of acute otitis media episodes in children aged 2–4 years: protocol for a pragmatic randomised controlled trial. BMJ Open, 2018, 8, e020941.	1.9	3
173	Examination of psychological risk factors for chronic pain following cardiac surgery: protocol for a prospective observational study. BMJ Open, 2019, 9, e022995.	1.9	3
174	Trends of paediatric head injury and acute care costs in Australia. Journal of Paediatrics and Child Health, 2022, 58, 274-280.	0.8	3
175	The Clinical Significance of Occult Gastrointestinal Primary Tumours in Metastatic Cancer: A Population Retrospective Cohort Study. Cancer Research and Treatment, 2018, 50, 183-194.	3.0	3
176	Paediatric traumatic brain injury severity and acute care costs. Archives of Disease in Childhood, 2022, 107, 497-499.	1.9	3
177	Economic Evaluation of In-Hospital Clinical Practices in Acute Injury Care: A Systematic Review. Value in Health, 2022, 25, 844-854.	0.3	3
178	Health Care Cost Matters for Homeless People: An Example of Costing Mental Health and Addiction Services in Homeless Shelters in Canada. International Journal of Mental Health and Addiction, 2008, 6, 476-483.	7.4	2
179	Oral Salt and Water versus Intravenous Saline for the Prevention of Acute Kidney Injury following Contrast-Enhanced Computed Tomography: Study Protocol for a Pilot Randomized Trial. Canadian Journal of Kidney Health and Disease, 2015, 2, 48.	1.1	2
180	Potential Effects of the Choice of Costing Perspective on Cost Estimates. Canadian Journal of Psychiatry, 2016, 61, 471-479.	1.9	2

#	Article	IF	CITATIONS
181	The Effect of Rehospitalization and Emergency Department Visits on Subsequent Adherence to Weight Telemonitoring. Journal of Cardiovascular Nursing, 2021, 36, 482-488.	1.1	2
182	Deciphering the Relationship Between Health Care Provider Burnout and Quality of Care. Annals of Internal Medicine, 2019, 171, 589.	3.9	2
183	Previous Out-of-Pocket Drug Expenditures and Patterns of Antidepressant Use among Workers Receiving Depression-Related Disability Benefits. Healthcare Policy, 2008, 4, e149-66.	0.6	2
184	A prospective multiple case study of the impact of emerging scientific evidence on established colorectal cancer screening programs: a study protocol. Implementation Science, 2012, 7, 51.	6.9	1
185	Reply to C.G. Azzoli et al and C. Chouaid et al. Journal of Clinical Oncology, 2014, 32, 3578-3579.	1.6	1
186	How can diagnostic assessment programs be implemented to enhance inter-professional collaborative care for cancer?. Implementation Science, 2014, 9, 4.	6.9	1
187	TELEPROM-G: A study evaluating access and care delivery of telehealth services among community-based seniors. , 2016, , .		1
188	Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View. Value in Health Regional Issues, 2019, 19, 138-144.	1.2	1
189	Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario. Journal of Oncology Pharmacy Practice, 2020, 26, 379-385.	0.9	1
190	Economic evaluation of intrahospital clinical practices in injury care: protocol for a 10-year systematic review. BMJ Open, 2020, 10, e034472.	1.9	1
191	Travel, Time, and Cost Savings Associated with a University Medical Center's Video Medical Interpreting Program. Telemedicine Journal and E-Health, 2020, 26, 1234-1239.	2.8	1
192	The cost-effectiveness of a culturally tailored parenting program: estimating the value of multiple outcomes. Cost Effectiveness and Resource Allocation, 2021, 19, 23.	1.5	1
193	Improving the Efficiency of Cost-effectiveness Analysis to Inform Policy Decisions in the Real World: Lessons from the Pharmacoeconomics Research Unit at Cancer Care Ontario. Profiles in Operations Research, 2013, , 399-416.	0.4	1
194	Cost-Effectiveness Analysis and Volume-Based Surgical Care. Journal of the American College of Surgeons, 2022, 234, 249-250.	0.5	1
195	Netâ€benefit regression with censored costâ€effectiveness data from randomized or observational studies. Statistics in Medicine, 2022, 41, 3958-3974.	1.6	1
196	GETTING MEN AND WOMEN RECEIVING DEPRESSION-RELATED SHORT-TERM DISABILITY BENEFITS BACK TO WORK: WHERE DO WE BEGIN?. Research in Human Capital and Development, 0, , 155-176.	0.1	0
197	Uncertain Times: Kenneth Arrow and the Changing Economics of Health Care. Contemporary Sociology, 2006, 35, 419-421.	0.0	0
198	The Need for Economic Evaluation in Primary Prevention of Cancer. Canadian Journal of Public Health, 2012, 103, e395-e396.	2.3	0

#	Article	lF	CITATIONS
199	The right amount of chemotherapy in non-curable disease: Insights from health economics. Journal of Cancer Policy, 2016, 10, 30-35.	1.4	0
200	Walk Long and Prosper: What Is the Optimal Way to Help People Achieve Their Goals?. Journal of General Internal Medicine, 2016, 31, 712-713.	2.6	0
201	1292â€Examining the relationship between depression symptom profiles and work productivity loss. , 2018, , .		0
202	Re: Choosing the discount rate in an economic analysis. EMA - Emergency Medicine Australasia, 2019, 31, 899-900.	1,1	0
203	T102. TELEPROM-Y: IMPROVING ACCESS AND EXPERIENCE OF MENTAL HEALTHCARE FOR YOUTH THROUGH VIRTUAL MODELS OF CARE. Schizophrenia Bulletin, 2020, 46, S269-S270.	4.3	0
204	Improving Access and Mental Health For Youth Using Smart Technologies. IET Smart Cities, 2021, 3, 41-51.	3.1	0
205	Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL). Blood, 2011, 118, 2068-2068.	1.4	0
206	Deriving Health Utility Values From a Health-Related Quality of Life Instrument in Non-Hodgkin Lymphoma Patients. Blood, 2011, 118, 2065-2065.	1.4	0
207	A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer Journal of Clinical Oncology, 2014, 32, 547-547.	1.6	0
208	Systemic treatment patterns in small bowel and appendiceal adenocarcinomas (SBA and AA): A population-based study Journal of Clinical Oncology, 2016, 34, 242-242.	1.6	0
209	Improving Access and Mental Health for Youth Through Virtual Models of Care. Lecture Notes in Computer Science, 2020, , 210-220.	1.3	0
210	Cost-effectiveness of patient observation on cranial CT use with minor head trauma. Archives of Disease in Childhood, 2022, 107, 712-718.	1.9	0
211	Determining the Impact of Establishing a Psychogeriatric Outreach Team Network in Long-Term Care. Psychiatric Services, 2011, 62, .	2.0	O